Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Journal of Pharmacology and Toxicology

Year: 2016  |  Volume: 11  |  Issue: 1  |  Page No.: 20 - 26

Antidiabetic Agent in Combination with Simvastatin Reduces Blood Glucose and Elevated Liver Enzymes Level in Diabetic Rats for Extended Period of Time

Mst. M. Begum, M.S. Rahman, R.R. Swarna, M. Das, A.H.M.R. Imon, I. Jahan, M. Rahman, Md. E. Haque, R.R. Saha, A.H.M. Quamruzzaman, Md. A. Obaida, M. Maniruzzaman, A. Islam, Md. T. Islam and A. Sarker


Background and Objective: Combination of dosages regimen of an antidiabetic agent (Glibenclamide) with a lipid lowering drug can be an effective medication for the patient with high blood glucose level and liver enzyme disfunctionality. The present study was undertaken to investigate the effect of a fixed dose combination of glibenclamide (1.2 mg/70 kg b.wt.) and simvastatin (10 mg/70 kg b.wt.) on blood glucose and liver enzymes dysfuntionality in alloxan-induced diabetic rats for an extended time period. Materials and Methods: Two protocols were developed to carry out the experiment. The first is designated as 4 weeks short-term and second one is termed as 12 weeks long-term treatment protocols, respectively. Diabetes Mellitus (DM) was induced by single intraperitoneal (i.p.) injection of freshly prepared alloxan solution in 0.9% saline. Diabetic rats received treatment with i.p., injection of glibenclamide (1.2 mg/70 kg b.wt.) and simvastatin (10 mg/70 kg b.wt.) for 4 weeks as monotherapy and combination therapy (glibenclamide 0.6 mg/70 kg b.wt., simvastatin 5 mg/70 kg b.wt.) for 12 weeks. Graph pad was used and the results were expressed as Mean±SEM. A one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test or students paired or unpaired t-test was used in the study where appropriate. Results: Results were considered to be significant when p-values were less than 0.05 (p<0.05). Combination therapy demonstrated a significant (p<0.05) decrease in blood glucose and liver enzymes elevation compared with diabetic control group. The study also demonstrated that the short term treatment has satisfactory effect on lowering SGPT by 41% and SGOT by 50%. Long term administration of combination therapy showed more significant (p<0.05) potentiality on lowering SGPT (46%) and SGOT (53%), respectively and this level remain steady during total treatment period. Conclusion: The present study demonstrates that combination of glibenclamide with simvastatin at the dose level tested exhibits significant glucose and liver enzymes lowering activity in alloxan induced diabetic rats. When monotherapy with oral antidiabetic agents fails, combination therapy with glibenclamide plus simvastatin seems to be stable and effective for the treatment of diabetes mellitus.

Cited References Fulltext